Next generation antidepressants with novel mechanisms for treatment resistant depression.
Mu-Hong Chen, Pei-Chi Tu, Tung-Ping Su
Progress in Brain Research 2023 DOI: 10.1016/bs.pbr.2023.02.005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Ketamine Neuroplasticity Psilocybin |
| Keywords | Consciousness Novel antidepressants Psychedelics hallucinogens Entheogens Psychoactive drugs Mood disorder care Breakthrough medications Neuroplasticity brain |
| Citations | 3 |
| Key findings | Psychedelic drugs like ketamine and psilocybin modulate NMDARs and 5-HTRs to rapidly alter consciousness and neuroplasticity, and have shown rapid and sustained antidepressant effects in treatment-resistant depression. |
Abstract
Evidence has suggested that the modulation of N-methyl-d-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.